Fabrizio Nelli

940 total citations
56 papers, 596 citations indexed

About

Fabrizio Nelli is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Fabrizio Nelli has authored 56 papers receiving a total of 596 indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 27 papers in Pulmonary and Respiratory Medicine and 8 papers in Epidemiology. Recurrent topics in Fabrizio Nelli's work include Lung Cancer Research Studies (22 papers), Lung Cancer Treatments and Mutations (17 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Fabrizio Nelli is often cited by papers focused on Lung Cancer Research Studies (22 papers), Lung Cancer Treatments and Mutations (17 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Fabrizio Nelli collaborates with scholars based in Italy, United States and Malaysia. Fabrizio Nelli's co-authors include Mario Lusini, Marcello Amato, Filippo de Marinis, Enzo Maria Ruggeri, Luca Moscetti, Giuliana D’Auria, Isabella Sperduti, Diana Giannarelli, Sara Ramponi and Alessandra Felici and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Scientific Reports.

In The Last Decade

Fabrizio Nelli

54 papers receiving 579 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fabrizio Nelli Italy 12 370 329 94 58 49 56 596
Rafael Núñez-Nateras United States 13 300 0.8× 150 0.5× 141 1.5× 34 0.6× 84 1.7× 25 586
Tushar Vora India 16 301 0.8× 172 0.5× 166 1.8× 146 2.5× 144 2.9× 85 772
Chonlakiet Khorprasert Thailand 10 263 0.7× 363 1.1× 206 2.2× 107 1.8× 16 0.3× 31 718
Hiroaki Shimmura Japan 18 253 0.7× 177 0.5× 472 5.0× 67 1.2× 48 1.0× 102 1.1k
C. Frederick LeMaistre United States 5 444 1.2× 351 1.1× 38 0.4× 87 1.5× 37 0.8× 5 702
John A. Mata United States 12 319 0.9× 67 0.2× 277 2.9× 79 1.4× 25 0.5× 29 691
Susan Heenan United Kingdom 12 148 0.4× 87 0.3× 297 3.2× 23 0.4× 24 0.5× 35 477
Levent Mert Günay Türkiye 9 214 0.6× 46 0.1× 76 0.8× 50 0.9× 86 1.8× 20 388
Sheryl Ogden United States 14 186 0.5× 162 0.5× 573 6.1× 155 2.7× 30 0.6× 21 915
Zachary Hamilton United States 15 371 1.0× 102 0.3× 289 3.1× 219 3.8× 33 0.7× 86 632

Countries citing papers authored by Fabrizio Nelli

Since Specialization
Citations

This map shows the geographic impact of Fabrizio Nelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fabrizio Nelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fabrizio Nelli more than expected).

Fields of papers citing papers by Fabrizio Nelli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fabrizio Nelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fabrizio Nelli. The network helps show where Fabrizio Nelli may publish in the future.

Co-authorship network of co-authors of Fabrizio Nelli

This figure shows the co-authorship network connecting the top 25 collaborators of Fabrizio Nelli. A scholar is included among the top collaborators of Fabrizio Nelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fabrizio Nelli. Fabrizio Nelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nelli, Fabrizio, Agnese Fabbri, Diana Giannarelli, et al.. (2024). Herpes zoster after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: a prospective study. Clinical and Experimental Medicine. 24(1). 13–13. 2 indexed citations
2.
Chilelli, Mario Giovanni, et al.. (2024). Long-Term Complete Response and Survival in Metastatic Extramammary Paget’s Disease Treated With Trastuzumab Plus Paclitaxel: A Case Report. Cureus. 16(4). e58924–e58924. 1 indexed citations
3.
4.
5.
Nelli, Fabrizio, Diana Giannarelli, Agnese Fabbri, et al.. (2023). Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors. Cancer Immunology Immunotherapy. 72(10). 3217–3228. 3 indexed citations
6.
7.
Nelli, Fabrizio, Agnese Fabbri, Diana Giannarelli, et al.. (2022). Peripheral lymphocyte subset counts predict antibody response after SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients: Results from the Vax-On-Profile study. International Immunopharmacology. 108. 108774–108774. 5 indexed citations
8.
Ruggeri, Enzo Maria, Fabrizio Nelli, Agnese Fabbri, et al.. (2021). Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study. ESMO Open. 7(1). 100350–100350. 6 indexed citations
9.
Minuti, Gabriele, Silvia Carpano, Ettore D’Argento, et al.. (2021). [Management of small cell lung cancer patient in the regions of Lazio, Umbria and Sardinia.]. PubMed. 112(10). 639–646. 1 indexed citations
10.
Nelli, Fabrizio, Agnese Fabbri, Luca Moscetti, et al.. (2020). Long-term outcome of pemetrexed maintenance for advanced nonsquamous non-small-cell lung cancer: a real-world observational cohort study. Recenti Progressi in Medicina. 111(12). 761–768. 2 indexed citations
11.
Roberto, Michela, Andrea Botticelli, Fabiana Letizia Cecere, et al.. (2019). L’immunoterapia nel tumore del polmone non a piccole cellule: ritorno al futuro. Recenti Progressi in Medicina. 110(12). 587–593. 1 indexed citations
12.
Grande, Roberta, Isabella Sperduti, Alain Gelibter, et al.. (2013). Changing monoclonal antibody keeping unaltered the chemotherapy regimen in metastatic colorectal cancer patients: is efficacy maintained?. SpringerPlus. 2(1). 185–185. 1 indexed citations
13.
Nelli, Fabrizio, et al.. (2006). Developing innovative strategies for advanced transitional cell carcinoma of the bladder. Expert Review of Anticancer Therapy. 6(1). 83–92. 4 indexed citations
14.
Ruggeri, Enzo Maria, Diana Giannarelli, Emilio Bria, et al.. (2006). Adjuvant chemotherapy in muscle‐invasive bladder carcinoma. Cancer. 106(4). 783–788. 53 indexed citations
15.
Trodella, L., Filippo de Marinis, Rolando Maria D’Angelillo, et al.. (2006). Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer. Lung Cancer. 54(3). 331–338. 10 indexed citations
16.
17.
Amato, Marcello, Mario Lusini, & Fabrizio Nelli. (2004). Epidemiology of Nephrolithiasis Today. Urologia Internationalis. 72(Suppl. 1). 1–5. 95 indexed citations
18.
Cappuzzo, Federico, Giovanni Selvaggi, Vanesa Gregorc, et al.. (2003). Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA‐bulky N2 and Stage IIIB nonsmall cell lung carcinoma. Cancer. 98(1). 128–134. 34 indexed citations
19.
Marinis, Filippo de, Maria Rita Migliorino, Luca Paoluzzi, et al.. (2003). Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer. Lung Cancer. 39(3). 331–338. 10 indexed citations
20.
Migliorino, M.R., Filippo de Marinis, Fabrizio Nelli, et al.. (2000). Gemcitabine and cisplatin as induction chemotherapy in stage IIIAN2/IIIB Non Small Cell Lung Cancer (NSCLC). A mono-institutional phase II study with 21 days schedule. Lung Cancer. 29(1). 113–113. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rafael Núñez-Nateras Breakdown of academic impact, for papers by Tushar Vora Breakdown of academic impact, for papers by Chonlakiet Khorprasert Breakdown of academic impact, for papers by Hiroaki Shimmura Breakdown of academic impact, for papers by C. Frederick LeMaistre Breakdown of academic impact, for papers by John A. Mata Breakdown of academic impact, for papers by Susan Heenan Breakdown of academic impact, for papers by Levent Mert Günay Breakdown of academic impact, for papers by Sheryl Ogden Breakdown of academic impact, for papers by Zachary Hamilton
Rankless by CCL
2026